Loading...

FITC anti-mouse IFN-γ Antibody

Pricing & Availability
Clone
XMG1.2 (See other available formats)
Regulatory Status
RUO
Other Names
Interferon-γ, Immune interferon, Type II interferon, T cell interferon, Macrophage-activating factor (MAF)
Isotype
Rat IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
XMG1.2_FITC_IFNgamma_Antibody_ICFC_1_090712
  • XMG1.2_FITC_IFNgamma_Antibody_ICFC_1_090712
  • XMG1.2_FITC_IFNgamma_Antibody_ICFC_2_090712
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
505805 25 µg 27€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
505806 100 µg 80€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

IFN-γ is a potent multifunctional cytokine which is secreted primarily by activated NK cells and T cells. Originally characterized based on anti-viral activities, IFN-γ also exerts anti-proliferative, immunoregulatory, and proinflammatory activities. IFN-γ can upregulate MHC class I and II antigen expression by antigen-presenting cells.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
E. coli-expressed, recombinant mouse IFN-γ
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The IFN-γ antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

ICFC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

ELISA1-4,11,14 or ELISPOT5 Detection: The biotinylated XMG1.2 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified R4-6A2 antibody (Cat. No. 505702/505706) as the capture antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard.
ELISA or ELISPOT Capture: The purified XMG1.2 antibody is useful as a capture antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with biotinylated R4-6A2 antibody (Cat. No. 505704) as the detection antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard. The LEAF™ purified antibody is suggested for ELISPOT capture (Cat. No. 505812).
Flow Cytometry7,8,12,13,16: The fluorochrome-labeled XMG1.2 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-γ-producing cells within mixed cell populations.
Neutralization1-3,9,10: The XMG1.2 antibody can neutralize the bioactivity of natural or recombinant IFN-γ. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse IFN-γ bioactivity in vivo and in vitro (Cat. No. 505812). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 505834) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).
Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining of frozen tissue sections6,22,23, and immunocytochemistry.
Note: For testing mouse IFN-γ in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 430801 to 430806) are specially developed and recommended.

Application References
  1. Abrams J, et al. 1992. Immunol. Rev. 127:5. (ELISA, Neut)
  2. Sander B, et al. 1993. J. Immunol. Meth. 166:201. (ELISA, Neut)
  3. Abrams J, et al. 1995. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.20. (ELISA, Neut)
  4. Yang X, et al. 1993. J. Immunoassay 14:129. (ELISA)
  5. Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.19. (ELISPOT)
  6. Sander B, et al. 1991. Immunol. Rev. 119:65. (IHC)
  7. Ferrick D, et al. 1995. Nature 373:255. (FC)
  8. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  9. Peterson KE, et al. 2000. J. Virol. 74:5363. (Neut)
  10. DeKrey GK, et al. 1998. Infect. Immun. 66:827. (Neut)
  11. Dzhagalov I, et al. 2007. J. Immunol. 178:2113. (ELISA)
  12. Lawson BR, et al. 2007. J. Immunol. 178:5366. (FC)
  13. Lee JW, et al. 2006. Nature Immunol. 8:181. (FC) PubMed
  14. Xu G, et al. 2007. J. Immunol. 179:5358. (ELISA) PubMed
  15. Montfort M, et al.2004. J. Immunol. 173:4084. PubMed
  16. Haring JS, et al. 2008. J. Immunol. 180:2855. (FC) PubMed
  17. Jordan JM, et al. 2008. Infect Immun. 76:3717. PubMed
  18. Tonkin DR, et al. 2008. J. Immunol. 181:4516. PubMed
  19. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
  20. Cui Y, et al. 2009. Invest. Ophth. Vis. Sci. 50:5811. (FC) PubMed
  21. Mykkanen OT, et al. 2014. PLoS One. 9:114790. PubMed
  22. Yokogawa M, et al. 2013. Mol. Carcinog. 52:760. (IHC)
  23. Mottram PL, et al. 1998. J Immunol. 161:602. (IHC)
Product Citations
  1. Chuang H, et al. 2014. Nat Commun. 5:4602. PubMed
  2. Li B, Schmidt N 2016. PLoS One. 11: 0162427. PubMed
  3. Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed
  4. Laura C Burzynski et al. 2019. Immunity. 50(4):1033-1042 . PubMed
  5. Wang X, et al. 2019. Cell Res. 29:787. PubMed
  6. Chen N, et al. 2021. Front Immunol. 12:756423. PubMed
  7. Yamazaki S, et al. 2022. Mucosal Immunol. :. PubMed
  8. Kim EH, et al. 2020. Elife. 9:00. PubMed
  9. Zhu C, et al. 2018. Sci Rep. 5.113194444. PubMed
  10. Onodera A, et al. 2017. J Immunol. 10.4049/jimmunol.1602129. PubMed
  11. Yu Y, et al. 2022. iScience. 25:105004. PubMed
  12. Di Martile M, et al. 2020. J Immunother Cancer. 8:. PubMed
  13. Ford K, et al. 2020. Cancer Res. 80:1846. PubMed
  14. Misumi I et al. 2019. Cell Rep. 27(5):1387-1396 . PubMed
  15. Kenichi Shimada et al. 2018. Immunity. 49(5):873-885 . PubMed
  16. Gupta SS, et al. 2019. Cell Rep. 29:1862. PubMed
  17. Magen A, et al. 2019. Cell Rep. 29:3019. PubMed
  18. Hewitson JP, et al. 2020. J Immunol. 204:2949. PubMed
  19. Gao Y, et al. 2020. Nat Cell Biol. 1064:22. PubMed
  20. Weigelin B, et al. 2015. Proc Natl Acad Sci U S A. 112:7551. PubMed
  21. Yang W, et al. 2020. Nat Commun. 3.553472222. PubMed
  22. Volpedo G, et al. 2022. NPJ Vaccines. 7:32. PubMed
  23. Isakova-Sivak I, et al. 2020. Vaccines (Basel). 8:00. PubMed
  24. Zhao B, et al. 2021. Cell Reports. 36(3):109401. PubMed
  25. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  26. Misumi I et al. 2019. Cell Rep. 27(2):514-524 . PubMed
  27. Cai B, et al. 2021. Mol Cancer. 20:165. PubMed
  28. Sehnert B, et al. 2022. Front Immunol. 13:921488. PubMed
  29. Wang Z, et al. 2020. Autophagy. 1:. PubMed
  30. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  31. Ni P, et al. 2014. J Immunol . 193:1778. PubMed
  32. Larena M, et al. 2011. J Virol. 85:5446. PubMed
  33. Chao CC, et al. 2020. Cell. 179(7):1483-1498.e22.. PubMed
  34. Lu Y, et al. 2020. Cell. 180(6):1081-1097. PubMed
  35. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  36. Sasaki K, et al. 2019. Nat Commun. 10:3878. PubMed
  37. Yang X, et al. 2019. Oncotarget. 10:4180. PubMed
  38. Khan IM, et al. 2021. Immunohorizons. 5:703. PubMed
  39. Sato Y, et al. 2021. J Clin Invest. Online ahead of print. PubMed
  40. Li H, et al. 2021. Nat Commun. 12:2773. PubMed
  41. Ontiveros-Padilla L, et al. 2021. Microorganisms. 9:. PubMed
  42. Wei F, et al. 2014. Cancer Res. 74:5989. PubMed
  43. Montel-Hagen A, et al. 2020. Cell Rep. 33:108320. PubMed
  44. Alessandrini F, et al. 2019. Oncogene. 38:4467. PubMed
  45. Sophie Thiemann et al. 2017. Cell host & microbe. 21(6):682-694 . PubMed
  46. He J, et al. 2020. Cell Reports. 29(9):2718-2730.e6.. PubMed
  47. Khakhum N, et al. 2021. NPJ Vaccines. 6:72. PubMed
  48. Zhao F, et al. 2022. Front Immunol. 13:873720. PubMed
  49. Ni P, et al. 2014. Mol Immunol. 62:199. PubMed
  50. Dar HY, et al. 2018. Sci Rep. 8:2503. PubMed
  51. Pu Y, et al. 2022. Transl Psychiatry. 12:223. PubMed
  52. Li Y, et al. 2015. J Nutr Biochem. Available online 8 August 2015. PubMed
  53. Dar HY, et al. 2018. Bone Rep. 8:46. PubMed
  54. Nika L, et al. 2019. Vaccines (Basel). 7. PubMed
  55. Hu Q, et al. 2018. Nat Biomed Eng. 0.660416667. PubMed
  56. Du Y, et al. 2022. Nat Commun. 13:231. PubMed
  57. Zhang L, et al. 2022. Front Immunol. 13:828263. PubMed
  58. Pardy RD, et al. 2021. Nat Commun. 12:4051. PubMed
  59. Gudgeon N, et al. 2022. Cell Rep. 40:111193. PubMed
  60. Stutz MD, et al. 2021. Immunity. 54(8):1758-1771.e7. PubMed
  61. Tartey S, et al. 2021. Cancer Research. 81(9):2358-2372. PubMed
  62. Cheng Y, et al. 2020. PLoS Pathog. 16:e1008569. PubMed
  63. Crooks SD, et al. 2022. Immunohorizons. 6:705. PubMed
  64. Ren Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  65. Chung NH, et al. 2022. Vaccine. 40:574. PubMed
  66. Baier FA, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:745. PubMed
  67. Gao X, et al. 2010. Mol Immunol. 47:2397. PubMed
  68. Kedzierski L, et al. 2014. PLoS Pathog. 10:1004134. PubMed
  69. White C, et al. 2015. J Immunol. 194:697. PubMed
  70. Sood S, et al. 2016. J Immunol. 197: 429 - 440. PubMed
  71. Deerhake ME, et al. 2021. Immunity. 54(3):484-498.e8. PubMed
  72. Ren W, et al. 2018. Mucosal Immunol. 12:531. PubMed
  73. Guo C, et al. 2017. Methods Mol Biol. 1709:345. PubMed
  74. Sun C, et al. 2022. J Adv Res. 35:71. PubMed
  75. Shen M, et al. 2022. Nat Cancer. 3:60. PubMed
  76. Liu B, et al. 2022. Mol Med Rep. 26:. PubMed
  77. Ni J, et al. 2020. Immunity. 52(6):1075-1087.e8. PubMed
  78. Vardhana SA, et al. 2020. Nat Immunol. 1.584722222. PubMed
  79. Pinget G, et al. 2016. Immunol Cell Biol. 10.1038/icb.2016.48. PubMed
  80. Gagnon JD, et al. 2019. Cell Rep. 28:2169. PubMed
  81. Ding P, et al. 2022. Bone Res. 10:42. PubMed
  82. Yang BH, et al. 2020. Cell Reports. 27(12):3629-3645.e6.. PubMed
  83. Montfort M, et al. 2004. J Immunol. 173:4084. PubMed
  84. Li Y, et al. 2021. Elife. 10:. PubMed
  85. Evgin L, et al. 2022. Sci Transl Med. 14:eabn2231. PubMed
  86. Gomez S, et al. 2022. J Immunother Cancer. 10:. PubMed
  87. Wu B, et al. 2021. Immunity. 54(2):308-323.e6. PubMed
  88. Lebrun A, et al. 2015. J Immunol. 195: 4358 - 4368. PubMed
  89. Li Z, et al. 2022. Nat Commun. 13:6321. PubMed
  90. Olivo Pimentel V, et al. 2021. J Immunother Cancer. 9:. PubMed
  91. Wang Y, et al. 2021. Nat Commun. 12:4964. PubMed
  92. Miyauchi E, et al. 2020. Nature. 585:102. PubMed
  93. Brenndörfer E, et al. 2014. J Immunol. 192:1671. PubMed
  94. M H, et al. 2016. Open Bio. 6: 150208. PubMed
  95. Fernández-Orth J, et al. 2020. Eur J Immunol. . PubMed
  96. Nakornpakdee Y, et al. 2018. Asian Pac J Allergy Immunol. 36:265. PubMed
  97. Zhang X, et al. 2021. Nat Commun. 12:4536. PubMed
  98. Harb H, et al. 2020. Nat Immunol. 1359:21. PubMed
  99. Yuan C, et al. 2015. Biochem Biophys Res Commun. 464: 249-255. PubMed
  100. Lee J, et al. 2007. Nat Immunol. 8:181. PubMed
  101. McCauley ME, et al. 2020. Nature. 585(7823):96-101. PubMed
  102. Moufarrij S, et al. 2020. Sci Rep. 10:3470. PubMed
  103. Li N, et al. 2022. Nat Commun. 13:7281. PubMed
  104. He X, et al. 2021. J Immunother Cancer. 9:. PubMed
  105. Zhu E, et al. 2014. J Immunol. 192:5599. PubMed
  106. Takahashi T, et al. 2017. J Exp Med. 10.1084/jem.20160247. PubMed
  107. Dai X, et al. 2021. Molecular Cell. 81(11):2317-2331.e6. PubMed
  108. Sade–Feldman M, et al. 2018. Cell. 175:998. PubMed
  109. Kong XF, et al. 2018. Nat Immunol. 19:973. PubMed
  110. Field CS, et al. 2020. Cell Metab. 31:422. PubMed
  111. Huang LJ, et al. 2021. Immunity. 54(8):1728-1744.e7. PubMed
  112. Ukidve A, et al. 2020. Proc Natl Acad Sci U S A. 117:17727. PubMed
  113. Zeng J, et al. 2020. Int J Biol Sci. 1.939583333. PubMed
  114. Ding Z, et al. 2017. Sci Rep. 10.1038/s41598-017-12488-z. PubMed
  115. Hao L, et al. 2021. Br J Pharmacol. 178:4726. PubMed
  116. Li J, et al. 2012. Arthritis Rheum. 64:1098. PubMed
  117. Zamora-Chimal J, et al. 2017. Immunobiology. 222(2):454-462. PubMed
  118. Wang J, et al. 2020. Cell. 183(7):1867-1883.e26. PubMed
  119. Sartorius R, et al. 2018. Front Immunol. 1.413888889. PubMed
  120. Dai B, et al. 2021. Cell Reports Medicine. 2(8):100381. PubMed
  121. Angelou CC, et al. 2020. Frontiers in Immunology. 2.586805556. PubMed
  122. Bing Wu et al. 2018. Immunity. 49(5):886-898 . PubMed
  123. Aggarwal N, et al. 2021. Cell Rep. 37:110170. PubMed
  124. Tseng SH, et al. 2021. J Biomed Sci. 28:63. PubMed
  125. Nakazawa S, et al. 2020. Sci Rep. 10:14559. PubMed
  126. Ren X, et al. 2021. Cell Death Dis. 12:484. PubMed
RRID
AB_315399 (BioLegend Cat. No. 505805)
AB_315400 (BioLegend Cat. No. 505806)

Antigen Details

Structure
Cytokine; dimer; 40-80 kD (Mammalian)
Bioactivity
Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APCs
Cell Sources
CD8+ and CD4+ T cells, NK cells
Cell Targets
T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts
Receptors
IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)
Cell Type
Tregs
Biology Area
Cell Biology, Immunology, Neuroinflammation, Neuroscience
Molecular Family
Cytokines/Chemokines
Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.
2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321.
3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571.
4. Gray P, et al. 1987. Lymphokines 13:151.

Regulation
Upregulated by IL-2, FGF-basic, EGF; downregulated by 1-α-25-Dihydroxy vitamin D3, dexamethasone
Gene ID
15978 View all products for this Gene ID
UniProt
View information about IFN-gamma on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 1    Revision Date: 11/30/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account